Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News DBV Technologies SA DBVT

Healthcare Biotechnology
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of... see more

Current News (NDAQ:DBVT)

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

GlobeNewswire 20 hours ago

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

GlobeNewswire 4 days ago

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

GlobeNewswire 9 days ago

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

GlobeNewswire 11 days ago

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

GlobeNewswire December 16, 2025

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025

GlobeNewswire December 2, 2025

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

GlobeNewswire November 11, 2025

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

GlobeNewswire November 4, 2025

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

GlobeNewswire November 3, 2025
View More News ››

Opinion & Analysis (NDAQ:DBVT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:DBVT)

Buy buddy buy because it's taking off this morning.

Otherwise FOMO for you fellas out there today
coolfooldumbguy - December 17, 2025

Buy buddy buy because it's taking off this morning.

It is starting to climb upwards again today and it's looking really good here for you fellas
coolfooldumbguy - March 28, 2025

Using technical analysis for this one.

Bought this stock for .98 per share and will be using my method of Dollar Cost Averaging for it this week.It seems to be a good company...
coolfooldumbguy - October 23, 2024
View more Bullboard ››

TomaGold Corp.

TomaGold Corp.

TomaGold Corporation, together with its subsidiaries, engages in the acquisition, exploration, assessment, and development of ...
View More »

Podcasts